Last reviewed · How we verify
bOPV (three dose)
bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis.
bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis. Used for Prevention of poliomyelitis caused by poliovirus types 1 and 3.
At a glance
| Generic name | bOPV (three dose) |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | vaccine |
| Target | Poliovirus types 1 and 3 |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
bOPV is a live attenuated vaccine containing weakened strains of poliovirus types 1 and 3. When administered orally, it replicates in the intestinal tract and triggers both mucosal and systemic immune responses, inducing the production of neutralizing antibodies and cellular immunity against these poliovirus serotypes. This protects vaccinated individuals from infection and disease caused by wild-type poliovirus.
Approved indications
- Prevention of poliomyelitis caused by poliovirus types 1 and 3
Common side effects
- Vaccine-derived poliovirus (VDPV) shedding
- Mild gastrointestinal symptoms
- Fever
Key clinical trials
- Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants (PHASE3)
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV) (PHASE4)
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults (PHASE1)
- Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine (PHASE3)
- Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China (PHASE4)
- A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals (PHASE3)
- Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules (PHASE4)
- Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bOPV (three dose) CI brief — competitive landscape report
- bOPV (three dose) updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI